FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W72033272> ?p ?o ?g. }

• W72033272 endingPage "287" @default.
• W72033272 startingPage "282" @default.
• W72033272 abstract "Abstract Both chemotherapy and chimeric anti-CD20 monoclonal antibodies are effective agents against B-cell non-Hodgkin lymphoma (NHL). However, patients achieving remission are at risk of relapse. To evaluate the effect of the antiangiogenic drug endostatin used alone and after the administration of cyclophosphamide (CTX) or the anti-CD20 antibody rituximab, we generated a new model of human NHL by transplanting Namalwa cells intraperitoneally into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. First, we determined the most effective treatment schedule for the drugs assessed. When administered alone, CTX (3 courses of 75 mg/kg of body weight given intraperitoneally), rituximab (3 courses of 25 mg/kg given intraperitoneally), and endostatin (5 courses of 50 μg given subcutaneously) delayed tumor growth, and CTX was the most effective in controlling bulky disease. When given after chemotherapy or immunotherapy, endostatin effectively induced tumor stabilization. When mice given CTX or rituximab on days 3, 5, and 7 after transplantation were randomly assigned to receive endostatin or phosphate-buffered saline on days 15 to 19, tumor growth was prevented in endostatin-treated mice as long as the drug was administered. Furthermore, administration of endostatin on days 25 to 29 after tumor regrowth still induced significant tumor regression, whereas CTX and rituximab were not effective. The specific antiangiogenic action of endostatin was confirmed by in vitro and in vivo studies indicating that the drug inhibited proliferation and induced apoptosis of endothelial (but not of NHL) cells. In conclusion, sequential administration of chemotherapy and endostatin seems promising for treating bulky NHL, and the less toxic sequential administration of rituximab and endostatin is promising for treating limited disease." @default.
• W72033272 created "2016-06-24" @default.
• W72033272 creator A5007502698 @default.
• W72033272 creator A5017608697 @default.
• W72033272 creator A5022225535 @default.
• W72033272 creator A5022585118 @default.
• W72033272 creator A5041579636 @default.
• W72033272 creator A5047468243 @default.
• W72033272 creator A5069836898 @default.
• W72033272 creator A5058953420 @default.
• W72033272 date "2000-07-01" @default.
• W72033272 modified "2023-10-16" @default.
• W72033272 title "Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma" @default.
• W72033272 cites W110134706 @default.
• W72033272 cites W1579297325 @default.
• W72033272 cites W1974847449 @default.
• W72033272 cites W2000000541 @default.
• W72033272 cites W2009886857 @default.
• W72033272 cites W2061524005 @default.
• W72033272 cites W2084223070 @default.
• W72033272 cites W2094022450 @default.
• W72033272 cites W2131798870 @default.
• W72033272 cites W2159679541 @default.
• W72033272 cites W2291615309 @default.
• W72033272 cites W2314190243 @default.
• W72033272 cites W2316160054 @default.
• W72033272 cites W2334437685 @default.
• W72033272 cites W2394519452 @default.
• W72033272 doi "https://doi.org/10.1182/blood.v96.1.282" @default.
• W72033272 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10891463" @default.
• W72033272 hasPublicationYear "2000" @default.
• W72033272 type Work @default.
• W72033272 sameAs 72033272 @default.
• W72033272 citedByCount "80" @default.
• W72033272 countsByYear W720332722012 @default.
• W72033272 countsByYear W720332722013 @default.
• W72033272 countsByYear W720332722014 @default.
• W72033272 countsByYear W720332722019 @default.
• W72033272 countsByYear W720332722020 @default.
• W72033272 crossrefType "journal-article" @default.
• W72033272 hasAuthorship W72033272A5007502698 @default.
• W72033272 hasAuthorship W72033272A5017608697 @default.
• W72033272 hasAuthorship W72033272A5022225535 @default.
• W72033272 hasAuthorship W72033272A5022585118 @default.
• W72033272 hasAuthorship W72033272A5041579636 @default.
• W72033272 hasAuthorship W72033272A5047468243 @default.
• W72033272 hasAuthorship W72033272A5058953420 @default.
• W72033272 hasAuthorship W72033272A5069836898 @default.
• W72033272 hasConcept C126322002 @default.
• W72033272 hasConcept C134018914 @default.
• W72033272 hasConcept C143998085 @default.
• W72033272 hasConcept C150903083 @default.
• W72033272 hasConcept C203014093 @default.
• W72033272 hasConcept C207001950 @default.
• W72033272 hasConcept C2776694085 @default.
• W72033272 hasConcept C2776755627 @default.
• W72033272 hasConcept C2779338263 @default.
• W72033272 hasConcept C2779468541 @default.
• W72033272 hasConcept C2780394083 @default.
• W72033272 hasConcept C2780653079 @default.
• W72033272 hasConcept C2911091166 @default.
• W72033272 hasConcept C502942594 @default.
• W72033272 hasConcept C555293320 @default.
• W72033272 hasConcept C55851684 @default.
• W72033272 hasConcept C71924100 @default.
• W72033272 hasConcept C75920679 @default.
• W72033272 hasConcept C86803240 @default.
• W72033272 hasConcept C98274493 @default.
• W72033272 hasConceptScore W72033272C126322002 @default.
• W72033272 hasConceptScore W72033272C134018914 @default.
• W72033272 hasConceptScore W72033272C143998085 @default.
• W72033272 hasConceptScore W72033272C150903083 @default.
• W72033272 hasConceptScore W72033272C203014093 @default.
• W72033272 hasConceptScore W72033272C207001950 @default.
• W72033272 hasConceptScore W72033272C2776694085 @default.
• W72033272 hasConceptScore W72033272C2776755627 @default.
• W72033272 hasConceptScore W72033272C2779338263 @default.
• W72033272 hasConceptScore W72033272C2779468541 @default.
• W72033272 hasConceptScore W72033272C2780394083 @default.
• W72033272 hasConceptScore W72033272C2780653079 @default.
• W72033272 hasConceptScore W72033272C2911091166 @default.
• W72033272 hasConceptScore W72033272C502942594 @default.
• W72033272 hasConceptScore W72033272C555293320 @default.
• W72033272 hasConceptScore W72033272C55851684 @default.
• W72033272 hasConceptScore W72033272C71924100 @default.
• W72033272 hasConceptScore W72033272C75920679 @default.
• W72033272 hasConceptScore W72033272C86803240 @default.
• W72033272 hasConceptScore W72033272C98274493 @default.
• W72033272 hasIssue "1" @default.
• W72033272 hasLocation W720332721 @default.
• W72033272 hasOpenAccess W72033272 @default.
• W72033272 hasPrimaryLocation W720332721 @default.
• W72033272 hasRelatedWork W1969260042 @default.
• W72033272 hasRelatedWork W1981555885 @default.
• W72033272 hasRelatedWork W2006274666 @default.
• W72033272 hasRelatedWork W2374533761 @default.
• W72033272 hasRelatedWork W2473286505 @default.
• W72033272 hasRelatedWork W2554200208 @default.

• next